Cargando…
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
BACKGROUND: Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most common NNRTI-resistant variants, and has a favorable and unique in vitro resistance profile. METHODS: DRIVE-AHEAD is a phase 3,...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355823/ https://www.ncbi.nlm.nih.gov/pubmed/30184165 http://dx.doi.org/10.1093/cid/ciy540 |
_version_ | 1783391396601790464 |
---|---|
author | Orkin, Chloe Squires, Kathleen E Molina, Jean-Michel Sax, Paul E Wong, Wing-Wai Sussmann, Otto Kaplan, Richard Lupinacci, Lisa Rodgers, Anthony Xu, Xia Lin, Gina Kumar, Sushma Sklar, Peter Nguyen, Bach-Yen Hanna, George J Hwang, Carey Martin, Elizabeth A |
author_facet | Orkin, Chloe Squires, Kathleen E Molina, Jean-Michel Sax, Paul E Wong, Wing-Wai Sussmann, Otto Kaplan, Richard Lupinacci, Lisa Rodgers, Anthony Xu, Xia Lin, Gina Kumar, Sushma Sklar, Peter Nguyen, Bach-Yen Hanna, George J Hwang, Carey Martin, Elizabeth A |
author_sort | Orkin, Chloe |
collection | PubMed |
description | BACKGROUND: Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most common NNRTI-resistant variants, and has a favorable and unique in vitro resistance profile. METHODS: DRIVE-AHEAD is a phase 3, double-blind, non-inferiority trial. Antiretroviral treatment–naive adults with ≥1000 HIV-1 RNA copies/mL were randomized (1:1) to once-daily, fixed-dose DOR at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to efavirenz at 600 mg, emtricitabine at 200 mg, and TDF at 300 mg (EFV/FTC/TDF) for 96 weeks. The primary efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 48 (Food and Drug Administration snapshot approach; non-inferiority margin 10%). RESULTS: Of the 734 participants randomized, 728 were treated (364 per group) and included in the analyses. At week 48, 84.3% (307/364) of DOR/3TC/TDF recipients and 80.8% (294/364) of EFV/FTC/TDF recipients achieved <50 HIV-1 RNA copies/mL (difference 3.5%, 95% CI, -2.0, 9.0). DOR/3TC/TDF recipients had significantly lower rates of dizziness (8.8% vs 37.1%), sleep disorders/disturbances (12.1% vs 25.2%), and altered sensorium (4.4% vs 8.2%) than EFV/FTC/TDF recipients. Mean changes in fasting low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) were significantly different between DOR/3TC/TDF and EFV/FTC/TDF (−1.6 vs +8.7 mg/dL and −3.8 vs +13.3 mg/dL, respectively). CONCLUSIONS: In HIV-1 treatment-naive adults, DOR/3TC/TDF demonstrated non-inferior efficacy to EFV/FTC/TDF at week 48 and was well tolerated, with significantly fewer neuropsychiatric events and minimal changes in LDL-C and non–HDL-C compared with EFV/FTC/TDF. CLINICAL TRIALS REGISTRATION: NCT02403674 |
format | Online Article Text |
id | pubmed-6355823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63558232019-02-08 Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial Orkin, Chloe Squires, Kathleen E Molina, Jean-Michel Sax, Paul E Wong, Wing-Wai Sussmann, Otto Kaplan, Richard Lupinacci, Lisa Rodgers, Anthony Xu, Xia Lin, Gina Kumar, Sushma Sklar, Peter Nguyen, Bach-Yen Hanna, George J Hwang, Carey Martin, Elizabeth A Clin Infect Dis Articles and Commentaries BACKGROUND: Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most common NNRTI-resistant variants, and has a favorable and unique in vitro resistance profile. METHODS: DRIVE-AHEAD is a phase 3, double-blind, non-inferiority trial. Antiretroviral treatment–naive adults with ≥1000 HIV-1 RNA copies/mL were randomized (1:1) to once-daily, fixed-dose DOR at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to efavirenz at 600 mg, emtricitabine at 200 mg, and TDF at 300 mg (EFV/FTC/TDF) for 96 weeks. The primary efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 48 (Food and Drug Administration snapshot approach; non-inferiority margin 10%). RESULTS: Of the 734 participants randomized, 728 were treated (364 per group) and included in the analyses. At week 48, 84.3% (307/364) of DOR/3TC/TDF recipients and 80.8% (294/364) of EFV/FTC/TDF recipients achieved <50 HIV-1 RNA copies/mL (difference 3.5%, 95% CI, -2.0, 9.0). DOR/3TC/TDF recipients had significantly lower rates of dizziness (8.8% vs 37.1%), sleep disorders/disturbances (12.1% vs 25.2%), and altered sensorium (4.4% vs 8.2%) than EFV/FTC/TDF recipients. Mean changes in fasting low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) were significantly different between DOR/3TC/TDF and EFV/FTC/TDF (−1.6 vs +8.7 mg/dL and −3.8 vs +13.3 mg/dL, respectively). CONCLUSIONS: In HIV-1 treatment-naive adults, DOR/3TC/TDF demonstrated non-inferior efficacy to EFV/FTC/TDF at week 48 and was well tolerated, with significantly fewer neuropsychiatric events and minimal changes in LDL-C and non–HDL-C compared with EFV/FTC/TDF. CLINICAL TRIALS REGISTRATION: NCT02403674 Oxford University Press 2019-02-15 2018-08-31 /pmc/articles/PMC6355823/ /pubmed/30184165 http://dx.doi.org/10.1093/cid/ciy540 Text en © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Articles and Commentaries Orkin, Chloe Squires, Kathleen E Molina, Jean-Michel Sax, Paul E Wong, Wing-Wai Sussmann, Otto Kaplan, Richard Lupinacci, Lisa Rodgers, Anthony Xu, Xia Lin, Gina Kumar, Sushma Sklar, Peter Nguyen, Bach-Yen Hanna, George J Hwang, Carey Martin, Elizabeth A Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial |
title | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial |
title_full | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial |
title_fullStr | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial |
title_full_unstemmed | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial |
title_short | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial |
title_sort | doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus–1 infection: week 48 results of the drive-ahead trial |
topic | Articles and Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355823/ https://www.ncbi.nlm.nih.gov/pubmed/30184165 http://dx.doi.org/10.1093/cid/ciy540 |
work_keys_str_mv | AT orkinchloe doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT squireskathleene doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT molinajeanmichel doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT saxpaule doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT wongwingwai doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT sussmannotto doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT kaplanrichard doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT lupinaccilisa doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT rodgersanthony doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT xuxia doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT lingina doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT kumarsushma doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT sklarpeter doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT nguyenbachyen doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT hannageorgej doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT hwangcarey doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT martinelizabetha doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial AT doravirinelamivudinetenofovirdisoproxilfumarateisnoninferiortoefavirenzemtricitabinetenofovirdisoproxilfumarateintreatmentnaiveadultswithhumanimmunodeficiencyvirus1infectionweek48resultsofthedriveaheadtrial |